Skip to main content
. 2020 Dec 16;11(5):1313–1325. doi: 10.1016/j.jcmgh.2020.12.009

Figure 4.

Figure 4

Prediction of clinical nonresponse to sorafenib using the cirrhotic PDX model. (A) Cirrhotic PDX derived from Patient B underwent treatment with 16 days of sorafenib (50 mg/kg for 4 days and then 100 mg/kg for a further 12 days or control for 16 days [n = 3 in each group], respectively). Representative MRIs of cirrhotic PDX derived from Patient B are shown before and immediately after completing treatment with sorafenib. (B) The waterfall plot of cirrhotic PDX tumor response to sorafenib and control determined by tumor volume on MRI immediately before and at the end of treatment. (C) Computed tomography scan of Patient B before treatment with sorafenib and repeated 2 months after treatment initiation. CT, computed tomography.